All In Biotech

Drug Trial Radar · NCT01986933

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY

Last checked: Nov 20, 2026Latest source record: Jan 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Nov 2013

Primary completion

Apr 2015

Study completion Jun 2016

Sponsor

Lead sponsor
Chugai PharmaceuticalIndustry
Sponsor type
Industry
First posted
Nov 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy

Conditions

  • Atopic Dermatitis

Interventions

  • nemolizumab (CIM331)Drug

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12Time frame: baseline to Week 12

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Anniston, Alabama

  • Site not named

    San Diego, California

  • Site not named

    Miami, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Bay City, Michigan

  • Site not named

    New York, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Charleston, South Carolina

  • Site not named

    Charleston, South Carolina

  • Site not named

    College Station, Texas

  • Site not named

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.